RADU, CLAUDIA-MARIA
 Distribuzione geografica
Continente #
NA - Nord America 5.775
EU - Europa 641
AS - Asia 345
SA - Sud America 4
AF - Africa 3
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.773
Nazione #
US - Stati Uniti d'America 5.775
CN - Cina 261
IT - Italia 218
DE - Germania 110
FI - Finlandia 101
SE - Svezia 97
GB - Regno Unito 56
VN - Vietnam 53
UA - Ucraina 25
SG - Singapore 16
IE - Irlanda 10
IN - India 10
NL - Olanda 8
FR - Francia 5
BR - Brasile 4
CH - Svizzera 3
ES - Italia 3
AU - Australia 2
EU - Europa 2
IR - Iran 2
LU - Lussemburgo 2
BE - Belgio 1
CZ - Repubblica Ceca 1
ID - Indonesia 1
JP - Giappone 1
KE - Kenya 1
NZ - Nuova Zelanda 1
OM - Oman 1
PL - Polonia 1
SZ - Regno dello Swaziland 1
ZA - Sudafrica 1
Totale 6.773
Città #
Fairfield 1.000
Woodbridge 684
Chandler 540
Ashburn 488
Ann Arbor 466
Houston 393
Seattle 390
Wilmington 340
Cambridge 327
Jacksonville 126
San Diego 102
Princeton 98
Padova 91
Beijing 90
Des Moines 68
Medford 68
Helsinki 55
Dong Ket 53
Boardman 47
Roxbury 44
Nanjing 30
London 20
Milan 19
Shenyang 17
Falls Church 14
Nanchang 14
New York 14
Guangzhou 12
Hebei 11
Jinan 11
Norwalk 10
Nürnberg 10
Changsha 8
Hefei 8
Los Angeles 8
Singapore 8
Legnaro 7
Bologna 6
Cagliari 6
Dublin 6
Jiaxing 6
Kharkiv 6
Kilburn 6
Ogden 6
Tianjin 6
Chicago 5
Redwood City 5
Washington 5
Ferentino 4
Kunming 4
Taiyuan 4
Chiswick 3
Detroit 3
Gunzenhausen 3
Indiana 3
Martinsicuro 3
Ningbo 3
Rockville 3
Tivoli 3
Afragola 2
Atlanta 2
Bassano Del Grappa 2
Borås 2
Boston 2
Brentwood 2
Capriate San Gervasio 2
Cardano al Campo 2
Dearborn 2
Frankfurt am Main 2
Haikou 2
Lappeenranta 2
Luxembourg 2
Madrid 2
Orange 2
Paris 2
Piacenza 2
Portland 2
Pune 2
Rocca d'Arazzo 2
Southwark 2
Stockholm 2
São Paulo 2
Taizhou 2
Zhengzhou 2
Asir 1
Auckland 1
Basel 1
Belluno 1
Berlin 1
Bern 1
Bilbao 1
Brussels 1
Buffalo 1
Cork 1
Dallas 1
Delhi 1
Dubbo 1
Edinburgh 1
Esslingen am Neckar 1
Falkenstein 1
Totale 5.856
Nome #
miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways 187
Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles? 182
Dual polarization of human alveolar macrophages progressively increases with smoking and COPD severity 171
Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients 167
Dynamics of circulating microparticles in obesity after weight loss 143
Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance 128
Potential role of thrombelastography in the monitoring of acquired factor VIII inhibitor hemophilia A: report on a 78-year-old woman with life-threatening bleedings. 127
Macrophage-secreted myogenic factors: a promising tool for greatly enhancing the proliferative capacity of myoblasts in vitro and in vivo 125
Changes in plasma circulating microvesicles in patients with HCV‐related cirrhosis after treatment with direct‐acting antivirals 121
Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. 119
Microparticles as biomarkers of venous thromboembolic events 118
Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis 116
X-linked thrombophilia with a mutant factor IX (factor IX Padua). 116
Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia 113
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms 111
Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells 110
Whole blood rotation thromboelastometry (ROTEM(®)) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V. 109
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. 108
Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S 106
New prothrombin mutation (Arg596Trp, Prothrombin Padua 2) associated with venous thromboembolism 105
Platelet factor V levels in moderate to severe congenital factor V deficiency. 103
Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: A role for circulating microparticles? 102
Studies on coagulation incompatibilities for xenotransplantation. 101
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events 99
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. 99
Effects of long-term administration of recombinant human protein C in xenografted primates. 98
Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. 97
MP062 EXPLORING ALBUMIN UPTAKE IN HUMAN PODOCYTES: A POSSIBLE INVOLVEMENT FOR THE TUBULAR UPTAKE MACHINERY 96
Similar hypercoagulable state and thrombosis risk in type I and type III proteinS-deficient individuals from mixed type I/III families. 94
Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women 94
Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. 94
Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis 90
Tailored prophylaxis with rFXIII (NovoThirteen ® ) in a young girl with severe FXIII deficiency and previous cephalohaematoma 89
Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct acting antivirals 88
Enhancing myoblast proliferation by using myogenic factors: a promising approach for improving fiber regeneration in sport medicine and skeletal muscle diseases 87
Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study 87
Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation. 85
Inherited thrombophilia and venous thromboembolism 82
Thrombin activatable fibrinolysis inhibitor in cancer patients with and without venous thromboembolism. 82
Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. 82
Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma 81
Similar hypercoagulable state and thrombosis risk in type Iand type III protein S-deficient individuals from families with mixed type I/IIIprotein S deficiency. 80
Reference values for thromboelastometry (ROTEM®) in cynomolgus monkeys (Macaca fascicularis). 80
The haemostatic system in acromegaly: a single-centre case–control study 78
Thromboelastometry profiles after “in vitro” addition of a new plasma-derived factor V concentrate to whole blood from parahaemophilia patients 77
Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. 76
Association between increased FVIIa-antithrombin complex/FVIIa ratio and pre-eclampsia. 75
The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells. 75
The aggressive EpCAM+CD45+ phenotype in serous epithelial ovarian cancer 74
Antisense-based RNA therapy of factor V deficiency: in vitro and ex vivo rescue of a F5 deep-intronic splicing mutation. 73
Circulating microparticles in carriers of prothrombin G20210A mutation. 72
Critical review of the evolution of extracellular vesicles’ knowledge: From 1946 to today 70
Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma 68
Circulating glial-derived and tissue factor bearing microparticles in patients with high grade glioma 68
Endocytosis of exogenous factor V by ex-vivo differentiated megakaryocytes from patients with severe parahaemophilia 68
Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis 68
Partial F8 gene duplication (Factor VIII Padua) associated with high factor VIII levels and familial thrombophilia 65
[Clinical significance of fluoroscopic patterns specific for the mitotic spindle in patients with rheumatic diseases]. 60
Increased Cardiovascular Risk Associated with Chemical Sensitivity to Perfluoro-Octanoic Acid: Role of Impaired Platelet Aggregation 60
Thrombin generation in patients with COVID-19 with and without thromboprophylaxis 60
Albumin uptake in human podocytes: A possible role for the cubilin-amnionless (CUBAM) complex 57
Incidence of VTE in asymptomatic children with deficiencies of antithrombin, protein C, and protein S: a prospective cohort study 54
Whole blood coagulation assessment using novel rotational thromboelastometry (ROTEM-R) in seen naive cynomologus monkeys 53
Microvesicles in bronchoalveolar lavage as a potential biomarker of COPD 53
Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study 53
Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: insights from renal ultrastructural findings.   53
Sounds Stimulation on In Vitro HL1 Cells: A Pilot Study and a Theoretical Physical Model 50
Levels of circulating microparticles in septic shock and sepsis-related complications: A case-control study 49
Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: A comparison between 3-factor and 4-factor prothrombin complex concentrates 48
Thrombin generation profile in cynomolgus monkey recipients of porcine neuronal xenograft 46
Clinical significance of fluoroscopic patterns specific for the mitotic spindle in patients with rheumatic diseases. 45
Evaluation of necroptosis related genes RIPK1, RIPK3 and MLKL-p immunogenicity in hepatocellular carcinoma 43
PAR-4/Ca2+-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes. 42
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings 39
Coagulation profile in cynomolgus monkey recipients of porcine neuronal xenograft: a preliminary study 37
Exploring albumin uptake in human podocytes: a possible involvement of the tubular endocytic machinery 37
CHARACTERIZATION OF CIRCULATING MICROPARTICLES DURING NORMAL PREGNANCY 34
Poly(lipoic acid)-based nanoparticles as a new therapeutic tool for delivering active molecules 33
Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19 30
Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study 28
Study of the origin of platelets coagulation protein S by human megakaryocyte cultures and characterization of platelets protein S in patients with inherited protein S deficiency 26
Exogenous human α-Synuclein acts in vitro as a mild platelet antiaggregant inhibiting α-thrombin-induced platelet activation 24
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study 23
Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3+ and CD8+ T cell density and predict prognosis in hepatocellular carcinoma 19
Macrophages-derived Factor XIII links coagulation to inflammation in COPD 7
In vitro and ex vivo rescue of a nonsense mutation responsible for severe coagulation factor V deficiency 6
Human parietal epithelial cells (PECs) and proteinuria in lupus nephritis: a role for ClC-5, megalin, and cubilin? 6
Increased Soluble Interleukin 6 Receptors in Fabry Disease 5
Profiling plasma alterations of extracellular vesicles in patients with acutely decompensated cirrhosis and bacterial infection 3
First Evidence of Mineralocorticoid Receptor Gene and Protein Expression in Rat and Human Thyroid Tissues and Cell Cultures 2
Reticulated platelets are increased and hyper-activated in patients with cirrhosis, especially those with poor outcome 2
Totale 6.866
Categoria #
all - tutte 23.898
article - articoli 23.169
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.067


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019420 0 0 0 0 0 0 0 0 0 0 235 185
2019/20201.401 164 64 10 91 135 101 144 171 200 174 80 67
2020/20211.368 49 89 107 96 81 55 52 153 152 223 132 179
2021/20221.244 52 73 160 92 95 103 39 170 78 26 101 255
2022/20231.043 175 115 31 143 174 115 6 71 136 11 51 15
2023/2024481 31 78 57 56 39 67 43 43 18 25 24 0
Totale 6.866